GlassScriptPhysician profile
Keith Anthony Williams
NPI 1689865891
$3,549.39
in general payments reported to CMS, 2019-2025
28 companies · $38.86 in 2025
The $38.86 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $730 · 2021: $1,033 · 2022: $658 · 2023: $384 · 2024: $14.07 · 2025: $38.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $632.07 | 2019-2023 | Relistor |
| Abbvie INC. | $445.92 | 2021-2023 | Ubrelvy, Qulipta |
| Collegium Pharmaceutical, INC. | $365.83 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $328.50 | 2021 | |
| Amgen INC. | $323.98 | 2019-2022 | |
| Pfizer INC. | $274.60 | 2019-2023 | |
| Scilex Pharmaceuticals INC. | $173.06 | 2019-2023 | Ztlido |
| Lilly USA, LLC | $149.07 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $144.36 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $84.53 | 2022 | |
| Biodelivery Sciences International, INC. | $83.95 | 2019-2020 | |
| Eisai INC. | $71.02 | 2020-2022 | |
| Redhill Biopharma INC. | $58.37 | 2021-2022 | |
| Novo Nordisk INC | $52.93 | 2024-2025 | Rybelsus, Ozempic |
| Hikma Pharmaceuticals USA | $52.57 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $46.08 | 2019 | |
| Pacira Therapeutics, INC. | $45.35 | 2021 | |
| Allergan, INC. | $30.91 | 2020 | |
| Averitas Pharma INC. | $29.52 | 2023 | Qutenza |
| Kowa Pharmaceuticals America, INC. | $28.34 | 2023 | Seglentis |
| Novartis Pharmaceuticals Corporation | $25.25 | 2019 | |
| Almatica Pharma LLC | $15.71 | 2022 | |
| Lundbeck LLC | $15.70 | 2023 | Vyepti |
| Indivior INC. | $14.89 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $14.80 | 2019 | |
| Kaleo, INC. | $14.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.97 | 2019 | |
| Grt US Holding, INC. | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.